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Type 1 DM is the most common metabolic disease 
in childhood with incidence rate varies greatly 
between different countries, within countries, and 
between different ethnic populations1, 2. Incidence 
of T1DM in Egypt in children less than 15 years 
ranged from 5% to 9.9%3. Celiac disease (CD) is 
one of the most frequent autoimmune disorders 
occurring in type-1 DM. The prevalence of CD 
among patients with type-1 DM varies in different 
geographical populations and is observed to range 
between 0.6 - 16.4% compared with 0.01- 0.03% in 
the general population4,5. Type-1 DM and CD show 
the same genetic background and an abnormal 
small intestinal immune response with 
inflammation and variable grades of enteropathy6. 
The inflammation in Celiac disease occurs 
primarily in the mucosa of the small intestine, 
which leads to villous atrophy. The clinical 
presentation of CD in type-1 DM is symptomless in 
approximately half of patients, but a more accurate 
analysis often discloses a wide array of symptoms 
suggestive of CD7.  
A definitive diagnosis of CD requires a jejunal 
biopsy demonstrating villous atrophy. Given the 
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transglutaminase IgA antibodies (tTG IgA) are considered specific and 
sensitive markers for screening of Celiac disease in more than 95 % of 
patients. Objective: Screening for the presence of serum tissue 
transglutaminase IgA antibodies (tTG ab) as a specific and sensitive 
biochemical marker for Celiac disease in patients with type-1DM and its 
relation to the clinical manifestations of those patients. Methods: One 
hundred-forty-nine patients with type-1 DM attending the out-patient clinic 
of endocrine and metabolism, Minia University Hospital were screened for 
the presence of serum tissue transglutaminase IgA antibodies during the 
period from March 2014 to November 2015. Results: Out of 149 patients 8 
patients (5.3%) were positive for IgA tTG antibodies. They who were 
predominantly of female gender (75% were females). According to each age 
group, there were four sero-positive cases in children (with age group 
between 9 and ≤ 12 years); two cases in adolescents (with age group 
between 12 and ≤ 16 years) and two cases in adults (with age group 16-21 
years). Intestinal manifestations, chronic diarrhea, recurrent abdominal 
pain/ distension, recurrent aphtha's stomatitis, anemia and bleeding 
tendency were significantly more common in sero-positive cases (P=0.001, 
0.001, 0.016, 0.00, 0.001and 0.04 respectively). All sero-positive cases 
(100%) had lower BMIs than normal. There were no correlations between 
the tTG antibodies levels and HbA1c levels. Conclusions: The presence of 
tTG IgA antibodies is associated with significant changes in the clinical 
status of patient with type-1 DM. Celiac disease related manifestations like 
weight loss; anemia and chronic diarrhea were more common in sero-
positive diabetic patients. Serological screening for CD should be performed 
in all patients with type-1DM for early diagnosis and prevention of 
complications. 
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invasive nature and cost of the biopsy, serologic 
and genetic laboratory tests may be used to identify 
individuals with a high probability of having Celiac 
disease8,9. Subsequently, those individuals with 
positive laboratory results should be referred for 
small intestinal biopsy and/or exposed to gluten free 
diet, thereby decreasing the number of unnecessary 
invasive procedures.  
The aim of this work was screening patients 
with type-1DM for the presence of serum tissue 
transglutaminase IgA antibodies (tTG ab) as a 
specific and sensitive biochemical marker for 
Celiac disease and its relation to the clinical 
manifestations of those patients.  
 
METHODS 
This study included one hundred-forty-nine (81 
females & 68 males) patients with type-1 DM 
attended the out-patient clinic of endocrine and 
metabolism of both internal medicine and pediatric 
departments, Minia University Hospital. Their ages 
ranged from 9 to 21 years screened for the presence 
of serum tissue transglutaminase IgA antibodies 
during the period from March 2014 to November 
2015. The diagnosis of type-1 DM was made 
according to the American Diabetes Association 
(ADA) using conventional criteria as classic 
clinical picture (polyuria, polydipsia and weight 
loss) and blood sugar > 200mg/dl and positive islet 
cell antibodies (ICA) and positive glutamic acid 
decarboxylase (GAD) antibodies 10. 
We excluded from the study all patients with 
uncontrolled complications of DM (like diabetic 
keto-acidosis, diabetic coma, diabetic nephropathy, 
neuropathy or retinopathy), past history of lactose 
intolerance (for children), irritable bowel syndrome 
(for adults), treatment with systemic immune-
modulatory agents in prior 30 days or treatment 
with systemic immune modifying biological agents 
e.g. infliximab in prior 6 months.   
All patients were on regular insulin therapy. 
They were submitted to full history taking and 
thorough clinical examination. Egyptian growth 
charts for children were used for assessment of 
weight, length and BMIs for children less than 18 
years. Urine and stool analysis were done in 
addition to the following laboratory investigations: 
CBC, serum creatinine, liver enzymes, HbA1c and 
tTG IgA antibodies.  
They were classified about to the presence or 
absence of IgA tissue transglutaminase antibodies 
(tTG ab) into sero-positive and sero-negative 
groups. IgA tTG antibodies were considered 
positive if their levels were more than 10 U/ml. 
Correlations between tTG ab and HbA1c as a 
marker for control of diabetes were studied.  
Written consents were taken from all adult 
patients and parents or care-givers of our children 
included in this study before conducting any steps 
and the study was approved by Faculty of Medicine 
Ethical Committee, Minia University. 
 
Laboratory studies 
Blood Sampling and Processing: About 7 mls of 
venous blood were taken from each patient by 
sterile venipuncture and divided as follow: One ml 
in EDTA containing tube for determination of CBC 
and HbA1c. Three mls were collected in dry tube, 
after clotting, the serum samples were obtained by 
centrifugation for 10 minutes at 3000 rpm and were 
stored frozen at (-20"C) until used. Three mls were 
collected in dry tube to be used in blood glucose, 
liver enzymes and renal function tests.  
Principle of tissue-transglutaminase IgA 
antibodies: Human recombinant tissue 
transglutaminase was bound to microwells 
antibodies against this antigen. Horseradish 
peroxidase (HRP) conjugated anti-human IgA 
immunologically detected the bound patient 
antibodies forming a conjugate/antibodies/antigen 
complex. We washed the microwells to remove 
unbound conjugate. An enzyme substrate in the 
presence of bound conjugate hydrolyzed and 
formed a blue color. We added an acid to stop the 
reaction forming a yellow product. The intensity of 
this yellow color is measured photo metrically at 
450 nm. The amount of color was directly 
proportional to the concentration of tTG IgA 
antibodies present in the original sample11,12. 
 
Statistical analysis 
Data entry and analysis were done using software 
(SPSS version 19). Graphics were done using 
Excel. Quantitative data were presented by mean 
and standard deviation, while qualitative data were 
presented by frequency distribution. Student t-test 
and Chi-square tests were used to compare 
qualitative variables between groups. The 
probability of less than 0.05 was used as a cut off 
for significant tests. 
 
RESULTS 
This study included 149 patients with type-1 DM, 
their ages ranged from 9 to 21 years with mean age 
of 12.9±6.4 years. Eighty-one patients (54.3%) 
were females and 68 (45.6%) were males. One 
hundred and thirty-five (90.6%) were delivered by 
vaginal delivery and 14 (9.4%) were delivered by 
cesarean section. One hundred and twenty-nine 
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(86.5%) were breast fed with mean duration 20.6 ± 
4.9 months and 20 (12.7%) were artificially fed. 
The mean time of gluten introduction was 6.9 ± 2.4 
months with earlier introduction in sero-positive 
than the sero-negative patients (4.5±1 versus 7.1 
±2.4, p=0.023).  
Out of one hundred and forty-nine diabetic 
patients only eight patients (5.4%) were positive for 
tTG IgA antibodies while 141 patients (94.6%) 
were negative. The antibodies titers were 
significantly higher in sero-positive than sero-
negative patients (15.5 ± 1.8 versus 0.79 ± 0.44 
respectively (p=0.001). (Table 1) 
Sero-positive   patients   had a significant 
predominance of female gender as from 8 patients 
with sero-positive, 6 patients (75%) were females 
(figure 1) with lower body mass indices (BMIs) 
than sero-negative patients (p- 0.047).  
The mean hemoglobin and corpuscular volumes 
were significantly lower in sero-positive patients 
(p= 0.032 and 0.017 respectively), while the mean 
values of liver enzymes were higher in sero-positive 
patients (AST = 86.2±9.5 IU/L versus 24.4±12.6 
IU/L and ALT= 84±12.9 IU/L versus 28±18.5 IU/L, 
P=0.005). (Table 1) 
Intestinal manifestations in the form of chronic 
diarrhea, recurrent abdominal pain and distension 
were significantly higher in sero-positive   than 
sero-negative patients (p- value= 0.001and 0.016 
respectively) (Table 2). 
Extra-intestinal manifestations, weight loss, 
anemia, bleeding tendency, bone aches and 
abnormalities in dental enamel were significantly 
increased in sero-positive compared to sero-
negative group (p 0.001, 0.001, 0.004, 0.004 
respectively) (Table 3). 
According to each age group, there were four 
sero-positive cases in children (with age group 
between 9 and ≤ 12 years); two cases in adolescents 
(with age group between 12 and ≤ 16 years) and 
two cases in adults (with age group 16-21 years). 
Also, intestinal and extra-intestinal manifestations 
were more frequent in children than in adolescents 
and adults (19,7 and 4 cases; p-value = 0.003 for 
intestinal and 27,10 and 11 cases; p-value=0.002 for 
extra-intestinal manifestations respectively)    
There were no correlations between the tTG 
antibodies levels HbA1c levels (Table 4).
 
 
Table 1. Laboratory data of studied patients 
 
Item Sero-positive 
n = 8 
Sero-negative 
n = 141 




10.2 ± 0.4 
10 






26.2 ± 0.73 
26.4 






77.6 ± 2.1 
77.7 






9 ± 1.9 
8.6 





















tTG IgA antibodies (U/ml) 
Mean ±SD 
Median 
15.5 ± 1.8 
15.2 
0.79 ± 0.44 
0.66 
0.001** 
*Significant        ** highly significant  
Hb: hemoglobin; MCH: mean corpuscular hemoglobin; MCV: mean corpuscular volume; TTG IgA: 













Table 2. Intestinal manifestations of studied groups 
 
Item Sero-positive 
n = 8 
Sero-negative 
n = 141 





































Table 3. Extra-intestinal manifestations of studied groups 
 
Item Sero-positive 
n = 8 
Sero-negative 
n = 141 





















































Table 4. Correlations between tTG-IGA antibodies 







Age (years)  0.12 (0.5) 0.05 (0.8) 
Weight (Kg)  0.51(0.09) 0.44 (0.06) 
BMI  -0.47 (0.02*) -0.45 (0.03*) 
Duration of DM (years) 0.62(0.04*) 0.51 (0.06) 
HbA1c %  0.24 (0.2) 0.20 (0.3) 
Urea (mg/dl  0.13 (0.5) 0.24 (0.2) 
Creatinine (mg/dl)  0.23 (0.2) 0.09 (0.6) 
ALT (u/l)  0.17(0.4) 0.24(0.2) 
AST (u/l) 0.21(0.3) 0.02(0.9) 
*Significant        ** highly significant  
BMI: body mass index; FBG: fasting blood glucose; 2-hour 
PPG:2-hours Post prandial glucose; HbA1c: glycated 
hemoglobin; ALT: Alanine transaminase; AST: Aspartate 
transaminase; tTG-IgA ab: tissue transglutaminase IgA antibodies   
 
 




Celiac disease and type-1 diabetes mellitus are 
autoimmune in origin and develop as a result of 
complex pathological mechanisms, involving 
several common genetic, environmental and 
immunological factors13. In terms of serology, 
Celiac disease is associated with a variety of 
autoantibodies, including endomysial, tissue 
transglutaminase (tTG) and deamidated gliadin 
antibodies. Among the most sensitive and specific 
auto-antibodies were tTG and deamidated gliadin 
antibodies. For individuals with moderately to 
strongly positive results, a diagnosis of Celiac 
disease is likely and the patient should undergo 
biopsy and /or exposed to gluten free diet as a 
therapeutic test to confirm the diagnosis14. 
In this study, out of 149 diabetic patients 8 
patients (5.3%) were positive for tTG IgA 
antibodies which are considered sensitive and 
specific auto-antibodies for Celiac disease and 141 
patients (94.7%) were negative with higher levels in 
sero-positive (15.5 ± 1.8) than sero-negative 
patients (0.79 ± 0.44). Sero-positive patients had a 
significant predominance of female gender as 6 out 
of 8 patients (75%) were females.  
These results were in agreement with other 
studies which reported that the prevalence of CD 
among patients with type-1 DM is approximately 
4% and this risk is highest with diabetes of early 
onset in childhood (age < 4 years), with the longer 
diabetes duration and the onset of DM before the 
age of 20 years14.  
These results were similar to the results of John 
et al.15, 2011 who reported an overall prevalence of 
(3.3%) for CD in type-1 DM. Also, higher 
percentage for tTG Ig A antibodies in type-1 DM 
patients (17%) was reported by Abdulrahman et 
al.16, 2012 who screened one hundred and six 
children with type-1 DM over a two-years period 
(2008–2010). 
The present study showed that the time of gluten 
introduction was significantly earlier in sero-
positive compared to sero-negative group 
(p=0.023). These results were in agreement with 
other studies 17,18 that reported an increased risk of 
CD in children exposed to gluten before 6 months 
with an incidence 4.24/1000 in children exposed to 
gluten before or at 4 months, compared with 
3.68/1000 in children with late gluten introduction 
after 6 months. Different results were reported by 
Aronsson et al. 19, 2015 who reported that gluten 
introduction either before 4 months or after 6 
months of age appeared to have no effect on Celiac 
disease risk. 
Common clinical manifestations in Celiac 
disease related to gastrointestinal inflammation 
include abdominal pain, malabsorption, diarrhea 
recurrent aphthous stomatitis and constipation. 
Clinical symptoms of Celiac disease are not 
restricted to the gastrointestinal tract. Other 
common manifestations of Celiac disease include 
failure to thrive (delayed puberty and short stature), 
iron deficiency, recurrent fetal loss, osteoporosis, 
chronic fatigue, dental enamel hypoplasia, and 
dermatitis herpetiformis20-22. 
The results of this study showed that CD 
symptoms (both intestinal and extra-intestinal) are 
much more frequent in children than in adolescents 
and adults and significantly higher in sero-positive 
than sero-negative patients. There were many 
studies reported similar results20-23. 
Similar results were reported by Ehsani-
Ardakani, et al.22, 2013 as 34.9% had at least one 
GI symptom as well as the majority of patients had 
diarrhea (13.6%) followed by dyspepsia and 
constipation (4.0%).  
The results of this study showed that extra-
intestinal manifestations like weight loss, anemia, 
bleeding tendency, bone aches abnormalities in 
dental enamel were significantly increased in sero-
positive compared to sero-negative group.  
Anemia demonstrated with low hemoglobin 
percentage and mean corpuscular volume was 
significantly more common in sero-positive   
patients. The results which are in agreement with 
other studies reported that anemia is the most 
presenting non-GI symptom in the majority of 
diabetic patients with Celiac disease,21.22. 
Elevated liver enzymes were more common in 
sero-positive compared to sero-negative patients 
reflecting the involvement of liver in patients with 
CD and type-1 DM.  These results were in 
agreement with other studies23,24. 
The results showed that there was no 
relationship between the tTG antibodies and the 
state of blood glucose control through Hb-A1c. 
These results were in agreement with others25. 
CD observed in type-1DM is classified as silent 
in approximately half of patients owing to the lack 
of symptoms suggestive for gluten-sensitive 
enteropathy. However, an accurate assessment of 
the clinical history and careful clinical examination 
allows the identification of more than one factor 
raising the suspicion of its diagnosis26.  
From the results of this study, serological 
screening for CD using tTG IgA antibodies is 
recommended for all patients with type-1DM for 
early diagnosis and prevention of complications due 
to high prevalence in this at-risk group for CD 
diagnosis with potential consequences of delayed 
diagnosis. 
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CONCLUSION 
The presence of tTG IgA antibodies is 
associated with significant changes in the clinical 
status of patient with type-1 DM. Weight loss, 
anemia, chronic diarrhea and other complications 
related to Celiac disease were more common in 
sero-positive diabetic patients. Serological 
screening for CD using tTG IgA antibodies should 
be performed in all patients with type-1DM for 
early diagnosis and prevention of complications. 
 
ABBREVIATIONS 
CD: Celiac disease, HLA: Human leucocytic 
antigen, T1DM: Type-1- diabetes mellitus, WHO: 
World Health Organization, CBC: Complete blood 
count, FBG: Fasting blood sugar, PPG: Post 
prandial glucose, HbA1c: glycated hemoglobin, 
TTG IgA ab.: tissue transglutaminase antibodies, 
IgA: Immunoglobulin A. 
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